What is NSIT's dividend yield?

Written by Editorial Team | Last Updated: August 2026

NSIT is the official stock ticker symbol for Insight Enterprises, Inc., a prominent global information technology hardware, software, and service solutions provider traded on the Nasdaq stock exchange. Insight Enterprises historically does not pay a regular cash dividend to its common shareholders, resulting in a dividend yield of zero percent. As a high-growth technology solutions enterprise, management prioritizes reinvesting generated capital and free cash flows into organic business expansion, strategic acquisitions, and share repurchases.

Related FAQs

Insight Enterprises, Inc. is a global information technology hardware, software, and service solutions integrator headquartered in Chandler, Arizona.

The stock ticker symbol NSIT represents Insight Enterprises, Inc., which is a prominent American multinational information technology hardware, software, and service provider publicly traded on the NASDAQ.

Insight Enterprises, Inc.

Insight Enterprises is widely respected as an exceptionally well-managed technology solutions provider renowned for its strategic vision, strong corporate culture, and excellent customer relationship management across business-to-business markets.

Insight Enterprises maintains a secure and prominent standing as a multi-billion-dollar enterprise that routinely occupies a high-ranking position within the core Fortune 500 list of the largest American corporations based on total annual revenue.

Employees working at Inspire Brands (the parent corporation managing prominent restaurant concepts like Arby's, Buffalo Wild Wings, and Sonic Drive-In) receive professional salaries and operational wages that vary by corporate administrative roles, s...

Insight Enterprises maintains robust cybersecurity protocols, secure digital supply chain infrastructures, and comprehensive financial compliance measures to ensure enterprise-level safety for its vendor networks, channel partners, and institutional ...

Insight Enterprises is widely recognized as a premier global information technology solutions provider that assists business and public sector clients with digital transformation, cloud migration, and hardware lifecycle management.

InterBank is a legitimate financial institution that provides a range of standard banking products, including savings and checking accounts, money market accounts, CDs, and mortgages [1.6.1].

Assessing whether Insight Enterprises (NSIT) represents a compelling equity purchase involves evaluating its position as a leading global solutions integrator providing digital innovation, cloud transformation, and hardware procurement services.

Yes, vintage glass and porcelain electrical insulators can be worth money, ranging from a few dollars to thousands of dollars depending on rarity, color, and manufacturer.

Determining if shares of Insight Enterprises are an attractive buy requires weighing its solid positioning in digital transformation against current corporate IT spending trends.

Insight Enterprises operates as an entirely authentic, highly established Fortune 500 technology corporation with a multi-decade operating history, thousands of enterprise employees, and physical offices spanning numerous international countries.

Intertek Group plc operates with a worldwide workforce of approximately forty-six thousand one hundred thirteen employees specializing in total quality assurance, systematic testing, inspection, and certification services.

Companies operating under the name Insight typically function as major information technology hardware and software solutions providers, corporate digital consultancies, or financial research enterprises.

Insight Enterprises, Inc. is a prominent American multinational information technology solutions provider and systems integrator that helps businesses accelerate their digital journeys.

Insmed Incorporated is a prominent, publicly traded biopharmaceutical enterprise headquartered in Bridgewater, New Jersey, focusing on the discovery, development, and commercialization of breakthrough therapeutic products for serious and rare disease...